Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab plus mFOLFOX6 in metastatic HER2-negative gastric/GE junction cancer
CTR20130959Phase 3Suspended
- Sponsor
- Roche
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of onartuzumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Roche. Started Apr 2014; status: suspended.
02
Drugs
onartuzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20130959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130959.